BEAMSTART Logo

Samsung Biologics wins $668 million CDMO deal with European pharma

Korea Economic Daily LogoKorea Economic Daily2h ago

Samsung Biologics wins $668 million CDMO deal with European pharma - Korea Economic Daily

Quick Summary:

The company has secured 11 deals to manufacture drugs for other companies so far this year.“We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients,” said John Rim, chief executive of Samsung Biologics.“As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies.

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combined $668 million with an unidentified European biopharmaceutical firm.

SK PHARMTECO, BINEX, ST PHARMKorea is home to the world’s leading contract drug manufacturers, including Samsung Biologics, SK Pharmteco, Binex Co.and ST Pharm Co.


More Pictures

Samsung Biologics wins $668 million CDMO deal with European pharma - Korea Economic Daily (Picture 1)Samsung Biologics wins $668 million CDMO deal with European pharma - Korea Economic Daily (Picture 2)Samsung Biologics wins $668 million CDMO deal with European pharma - Korea Economic Daily (Picture 3)Samsung Biologics wins $668 million CDMO deal with European pharma - Korea Economic Daily (Picture 4)Samsung Biologics wins $668 million CDMO deal with European pharma - Korea Economic Daily (Picture 5)

or

Article Details

Category: Economy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-20 @ 17:42:23 (2 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 706 words

Reading Time: 4 minutes read

Sentences: 32 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 23717412

View Article Analysis

About Korea Economic Daily

Korea Economic Daily Logo

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 16 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 12 minutes ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Samsung Biologics wins $668 million CDMO deal with European pharma" has 706 words across 32 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Which news outlet covered this story?

The story "Samsung Biologics wins $668 million CDMO deal with European pharma" was covered 2 hours ago by Korea Economic Daily, a news publisher based in South Korea.

How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.

The outlet is headquartered in South Korea and publishes an average of 16 news stories per day.

It's most recent story was published 12 minutes ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #23717412
  • URL: https://beamstart.com/news/samsung-biologics-wins-668-million-17320944143555

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.